Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $40,619.60 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 3,115 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the sale, the chief financial officer directly owned 256,725 shares in the company, valued at $3,347,694. The trade was a 1.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.17, for a total transaction of $245,910.24.

Adaptive Biotechnologies Stock Up 7.7%

Shares of NASDAQ ADPT traded up $1.00 during midday trading on Wednesday, reaching $13.96. 1,918,799 shares of the stock were exchanged, compared to its average volume of 1,623,319. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -42.30 and a beta of 2.16. Adaptive Biotechnologies Corporation has a twelve month low of $8.50 and a twelve month high of $20.76. The firm has a 50-day simple moving average of $13.81 and a two-hundred day simple moving average of $15.65.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. TD Cowen increased their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Morgan Stanley decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV purchased a new position in Adaptive Biotechnologies in the 1st quarter valued at $45,000. Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at $51,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.